Immunosuppression for interstitial lung disease in systemic sclerosis

被引：18

作者：

Cappelli, Susanna ^{[1
]}

Guiducci, Serena ^{[1
]}

Randone, Silvia Bellando ^{[1
]}

Cerinic, Marco Matucci ^{[1
]}

机构：

[1] Univ Florence, DENOthe Ctr, Dept Biomed, Div Rheumatol, Viale Pieraccini 18, I-50139 Florence, Italy

来源：

EUROPEAN RESPIRATORY REVIEW | 2013年 / 22卷 / 129期

关键词：

D O I：

10.1183/09059180.00001813

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

The efficacy of immunosuppressors in the treatment of systemic sclerosis-interstitial lung disease is still matter of controversy. In this review we will analyse the evidence that immunosuppressors, despite not being able to reverse fibrotic changes, may help in slowing disease progression. Induction treatment with cyclophosphamide should be started as soon as possible in patients at risk for progression. Mycophenolate mofetil and rituximab have to be considered in patients who are unable to tolerate cyclophosphamide. After remission, maintenance treatment with mycophenolate mofetil or azathioprine should be started in order to preserve the benefits achieved during the induction treatment.

引用

页码：236 / 243

页数：8

共 73 条

[61] Mortality and risk factors of scleroderma renal crisis:: a French retrospective study of 50 patients [J].

Teixeira, L. ;

Mouthon, L. ;

Mahr, A. ;

Berezne, A. ;

Agard, C. ;

Mehrenberger, M. ;

Noel, L-H ;

Trolliet, P. ;

Frances, C. ;

Cabane, J. ;

Guillevin, L. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (01) :110-116

[62] Haematopoietic stem cell transplantation for the treatment of systemic sclerosis and other autoimmune disorders [J].

Tyndall, A ;

Matucci-Cerinic, M .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2003, 3 (07) :1041-1049

[63]

VandenHoogen FHJ, 1996, BRIT J RHEUMATOL, V35, P364

[64]

Vanthuyne M, 2007, CLIN EXP RHEUMATOL, V25, P287

[65] Treatment of Systemic Sclerosis Complications: What to Use When First-Line Treatment Fails-A Consensus of Systemic Sclerosis Experts [J].

Walker, Kyle M. ;

Pope, Janet .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2012, 42 (01) :42-55

[66] Clinical risk assessment of organ manifestations in systemic sclerosis:: a report from the EULAR Scleroderma Trials And Research group database [J].

Walker, U. A. ;

Tyndall, A. ;

Czirjak, L. ;

Denton, C. ;

Farge-Bancel, D. ;

Kowal-Bielecka, O. ;

Mueller-Ladner, U. ;

Bocelli-Tyndall, C. ;

Matucci-Cerinic, M. .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (06) :754-763

[67] The clinical utility of bronchoalveolar lavage in diffuse parenchymal lung disease [J].

Wells, A. U. .

EUROPEAN RESPIRATORY REVIEW, 2010, 19 (117) :237-241

[68] Pulmonary complications: one of the most challenging complications of systemic sclerosis [J].

Wells, A. U. ;

Steen, V. ;

Valentini, G. .

RHEUMATOLOGY, 2009, 48 :40-44

[69] FIBROSING ALVEOLITIS ASSOCIATED WITH SYSTEMIC-SCLEROSIS HAS A BETTER PROGNOSIS THAN LONE CRYPTOGENIC FIBROSING ALVEOLITIS [J].

WELLS, AU ;

CULLINAN, P ;

HANSELL, DM ;

RUBENS, MB ;

BLACK, CM ;

NEWMANTAYLOR, AJ ;

DUBOIS, RM .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (06) :1583-1590

[70]

Yanaba K, 2004, J RHEUMATOL, V31, P1112

← 1 2 3 4 5 6 7 8 →